GlassScriptPhysician profile
Marianna Strakhan
NPI 1144489022
$2,257.93
in general payments reported to CMS, 2019-2025
21 companies · $79.75 in 2025
The $79.75 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $573 · 2022: $324 · 2023: $417 · 2024: $141 · 2025: $79.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $505 · Education: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $504.93 |
| Education | $132.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $470.81 | 2019-2024 | Opdivo |
| Astrazeneca Pharmaceuticals LP | $259.11 | 2019-2025 | Lynparza |
| Amgen INC. | $239.80 | 2019-2020 | |
| Puma Biotechnology, INC. | $233.79 | 2019-2020 | |
| Janssen Biotech, INC. | $196.93 | 2020-2022 | |
| Eisai INC. | $141.27 | 2019-2023 | |
| Pharmacyclics LLC, An Abbvie Company | $116.04 | 2020 | |
| Novartis Pharmaceuticals Corporation | $112.90 | 2019-2022 | |
| Incyte Corporation | $101.15 | 2022-2023 | |
| Stemline Therapeutics INC. | $97.44 | 2023 | Orserdu |
| Pfizer INC. | $75.03 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $53.85 | 2019-2022 | |
| Cumberland Pharmaceuticals, INC. | $24.49 | 2022 | |
| Sirtex Medical INC | $23.18 | 2022 | |
| Lilly USA, LLC | $20.61 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $18.68 | 2022 | |
| Adaptive Biotechnologies Corporation | $16.42 | 2025 | Clonoseq |
| Rigel Pharmaceuticals, INC. | $15.84 | 2025 | Tavalisse |
| Daiichi Sankyo INC. | $14.31 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.16 | 2019 | |
| Beigene USA, INC. | $12.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marianna Strakhan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.